HMG (Human Menopausal Gonadotropin) Research Guide — FSHR/Gs/cAMP Sertoli Cell Mechanism, Spermatogenesis & Folliculogenesis Biology (2026)
- HMG (human menopausal gonadotropin; hMG) is a urinary-derived glycoprotein preparation containing both FSH (follicle-stimulating hormone) and LH (luteinizing hormone) activity, isolated from the urine of postmenopausal women. Original preparations (Pergonal) contained approximately 1:1 FSH:LH activity with substantial urinary protein contamination; modern highly purified preparations (hp-hMG; Menopur) achieve greater FSH receptor specificity with significantly reduced inactive proteins. YPB offers research-grade HMG as YPB.258 (Research Use Only).
- FSH mechanism: FSH binds the FSHR (FSH receptor; Gs-coupled GPCR) on Sertoli cells in the testis and granulosa cells in the ovary. FSHR → Gs → adenylyl cyclase → cAMP ↑ → PKA → CREB activation → gene programs that support spermatogenesis: androgen-binding protein (ABP), inhibin B, GDNF, activin, testis-specific proteins; also drives Sertoli cell proliferation (determines spermatogenic capacity quota) and regulates blood-testis barrier (BTB) tight junction proteins. In granulosa cells: FSH drives folliculogenesis, CYP19A1/aromatase upregulation (estradiol production), follicle growth, antrum formation, LH receptor expression.
- Research applications: HMG is primarily used in the combined HCG + HMG protocol for spermatogenesis induction in hypogonadotropic hypogonadism research — HCG provides the Leydig cell testosterone signal (intratesticular T); HMG provides the FSH-mediated Sertoli cell support signal. Neither compound alone can replicate the complete two-gonadotropin signaling environment required for spermatogenesis. Published clinical data: combined HCG + FSH/HMG induces sperm production in 70–90% of hypogonadotropic hypogonadism models. YPB.258. Research Use Only (RUO). Updated April 2026.
- WADA context: HMG is prohibited in male athletes by WADA (S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics) because its LH activity stimulates endogenous testosterone production via Leydig cells. The FSH activity itself is not the WADA rationale; the LH component is. Research Use Only (RUO). Updated April 2026.
What Is HMG and Why Is It the Essential HCG Research Complement?
FSHR/Gs/cAMP Sertoli Cell Pathway
HCG Complement for Spermatogenesis
HMG is the pharmacological complement to HCG in reproductive endocrinology: HCG provides the LH-like signal to Leydig cells (testosterone production); HMG provides the FSH signal to Sertoli cells (germ cell support). Updated April 2026. Understanding why both are required — and why HCG alone cannot complete spermatogenesis — requires understanding the fundamental two-cell, two-gonadotropin model of spermatogenesis that has been established in both genetic knockout mouse models and in clinical hypogonadotropic hypogonadism data.
The foundational insight: FSH and LH act on completely different cell types within the testis. LH (and HCG) acts on Leydig cells in the interstitial space, driving testosterone synthesis. FSH acts exclusively on Sertoli cells lining the seminiferous tubules. Sertoli cells are the “nurse cells” of spermatogenesis: they provide the physical scaffold, nutritional support, growth factors, and immunological protection (blood-testis barrier) that germ cells require to complete the 72-day spermatogenic cycle. Without FSH-stimulated Sertoli cell support, Leydig cell-derived testosterone cannot complete spermatogenesis regardless of its intratesticular concentration. Conversely, FSH alone cannot drive spermatogenesis without the intratesticular testosterone provided by LH/HCG-stimulated Leydig cells. HMG, containing both FSH and LH activity, provides both signals — or can be combined with HCG for protocols where LH activity augmentation is needed.
Key Characteristics
| Parameter | Value |
|---|---|
| Full Name | Human menopausal gonadotropin; hMG; menotropin |
| Source | Isolated from urine of postmenopausal women (in whom pituitary FSH and LH are elevated due to absence of ovarian estrogen feedback); highly purified preparations reduce inactive urinary proteins |
| Composition | Contains both FSH and LH activity; approximately 1:1 FSH:LH activity ratio in standard preparations; highly purified (hp-hMG) preparations achieve greater FSHR specificity with reduced LH activity and inactive proteins |
| YPB SKU | YPB.258 |
| FSH Receptor (FSHR) | Gs-coupled GPCR on Sertoli cells (testis) and granulosa cells (ovary); exclusive gonadal expression in males; the primary pharmacological target for HMG’s spermatogenesis-supporting activity |
| FSH Signal Cascade | FSHR → Gs → adenylyl cyclase → cAMP ↑ → PKA → CREB → gene programs: ABP (androgen-binding protein), inhibin B, GDNF, activin, Sertoli cell proliferation, BTB tight junction proteins |
| LH Activity | Binds LHCGR on Leydig cells (same receptor as HCG and endogenous LH); provides testosterone stimulus alongside FSH; shorter half-life than HCG (∼6h vs. 24h) |
| FSH Half-Life | ~24–36 hours (longer than LH due to sialic acid content; shorter than HCG); supports multi-day dosing intervals in fertility research protocols |
| Sertoli Cell Functions | FSH-driven: Sertoli cell proliferation (determines spermatogenic quota); ABP secretion (concentrates testosterone in seminiferous tubule); inhibin B production (negative feedback to pituitary); BTB tight junctions (immune privilege); GDNF (spermatogonial stem cell maintenance); activin (germ cell differentiation) |
| Granulosa Cell Functions | FSH-driven: follicle growth; CYP19A1/aromatase induction (estradiol production from androgens); LH receptor upregulation (primes for LH surge response); antrum formation; inhibin A production |
| FDA Status | research-grade compound equivalents (Menopur, Repronex, Pergonal) for ovulation induction and ART; research-grade HMG is not equivalent. Research Use Only (RUO). |
| WADA Status | Prohibited in males — S2 (LH activity stimulates endogenous testosterone). Not prohibited for females. |
| Storage | Lyophilized: −20°C. Reconstituted: sterile water; 2–8°C, use within 28 days. Glycoprotein: no vortex; gentle reconstitution. |
How Does HMG Work? FSHR/Gs/cAMP Sertoli Cell Cascade
The Two-Cell, Two-Gonadotropin Spermatogenesis Model
Spermatogenesis requires the coordinated action of two pituitary gonadotropins on two different testicular cell types: (1) LH acting on Leydig cells → intratesticular testosterone; and (2) FSH acting on Sertoli cells → germ cell support. These two signals are not redundant — they are parallel and both necessary. This principle was elegantly demonstrated in genetic knockout mouse models: LHCGR knockout (LuRKO) mice lack all LH/HCG signaling; they produce minimal testosterone and are infertile. FSHR knockout (FSHRKO) mice retain LH-driven testosterone but lack FSH-Sertoli cell signaling; they show severely impaired spermatogenesis and fertility despite normal testosterone. Only when both pathways are intact is complete, quantitatively normal spermatogenesis achieved. This two-signal model is the mechanistic basis for combined HCG + HMG fertility protocols: HCG provides signal 1 (Leydig/testosterone); HMG provides signal 2 (Sertoli/FSH).
FSH → FSHR → cAMP/PKA/CREB Sertoli Cell Program
FSH binds the FSHR (FSH receptor) on Sertoli cells. FSHR is a Gs-coupled GPCR with a large N-terminal extracellular domain that forms the high-affinity FSH binding site. Activation drives Gs → adenylyl cyclase → cAMP ↑ → PKA → phosphorylation of CREB and related transcription factors. The FSHR/cAMP/PKA/CREB cascade drives a specific Sertoli cell gene program: androgen-binding protein (ABP; concentrates testosterone within the seminiferous tubule lumen to the supraphysiological levels required for spermatogenesis); inhibin B (feedback suppression of pituitary FSH, measured clinically as a biomarker of Sertoli cell function); GDNF (glial cell line-derived neurotrophic factor; maintains spermatogonial stem cell self-renewal); activin and follistatin (regulate germ cell differentiation pace); BTB tight junction proteins (occludin, claudin-11; maintain the blood-testis barrier that creates immune privilege for post-meiotic germ cells). FSH also drives Sertoli cell proliferation in the prepubertal testis, establishing the Sertoli cell “quota” that determines the organ’s lifetime spermatogenic capacity.
What Research Applications Has HMG Been Studied For?
Male Infertility: Spermatogenesis Induction (Combined with HCG)
The primary research and wellness support of HMG is as the FSH component of combined HCG + HMG/FSH protocols for spermatogenesis induction in hypogonadotropic hypogonadism. In this model, HCG is used to provide Leydig cell testosterone; once adequate testicular volume and intratesticular testosterone are established (typically after 3–6 months of HCG alone), HMG is added to provide the FSH signal to Sertoli cells that initiates and supports the spermatogenic process. Published clinical data document sperm induction in 70–90% of properly selected hypogonadotropic hypogonadism subjects with combined HCG + HMG/FSH protocols. The timing of HMG addition and the FSH dose are active research questions for optimizing outcomes in men with pre-existing testicular deficiency (e.g., cryptorchidism history, varicocele).
Female Fertility: Folliculogenesis and ART Support
In females, HMG provides both FSH (follicle growth, granulosa cell aromatase/estradiol, antrum formation) and LH (theca cell androgen production, which granulosa cells convert to estradiol via aromatase). This dual activity makes HMG particularly useful for researching controlled ovarian stimulation (COS) for IVF: FSH drives multiple follicle recruitment and growth; LH supports the androgen substrate for estradiol synthesis. The FSH-driven upregulation of LH receptors on pre-ovulatory granulosa cells is the molecular priming that makes them responsive to the HCG ovulation trigger. HMG is the primary ovarian stimulation tool in ART research protocols studying folliculogenesis, granulosa cell biology, and cumulus-oocyte complex maturation.
FSHR Pharmacology Research
HMG is the reference agonist for FSHR pharmacology research in both testicular (Sertoli cell) and ovarian (granulosa cell) models. FSH/FSHR biology is an active research area: FSHR gain-of-function mutations producing ligand-independent cAMP have been described; FSHR loss-of-function mutations cause spermatogenic failure (males) and primary amenorrhea (females); FSHR polymorphisms (Ala307Thr/Ser680Asn) affect ovarian response to exogenous FSH in fertility treatments. HMG provides the FSH agonist stimulus for these pharmacological research designs.
What Does the Research Data Show?
| Research Area | Model / Evidence | Key Finding & Notes | Year(s) |
|---|---|---|---|
| HCG + FSH/HMG for hypogonadotropic hypogonadism | Clinical (men with hypogonadotropic hypogonadism) | Combined HCG + FSH/HMG induces spermatogenesis in 70–90% of men; HCG alone insufficient for complete sperm production; FSH/Sertoli cell signal required for germ cell maturation. Standard protocol: HCG for 3–6 months first (establish testicular testosterone/volume), then add HMG/FSH. Well established in multiple cohort studies; no serious adverse events from the combined protocol. | Multiple |
| FSHRKO knockout mouse model | Genetic (FSHR knockout mice) | Male FSHRKO mice: severely impaired spermatogenesis and fertility despite normal LH-driven testosterone; confirms FSH-Sertoli cell signaling is independently required. Female FSHRKO: complete folliculogenesis block at primary follicle stage, demonstrating FSH is mandatory for follicular growth beyond primary stage in humans (contradicting earlier dogma of gonadotropin-independent early folliculogenesis). | 2021 (review) |
| LHβ mutation (minimal testosterone) with maintained spermatogenesis | Clinical case (man with mutant LH β-subunit) | Complete spermatogenesis maintained despite testosterone production at 1–2% of normal; challenges the intratesticular testosterone dogma; implies FSH/Sertoli signaling can partially compensate for reduced testosterone; low-dose T supplementation in LuRKO mice can rescue spermatogenesis. (Huhtaniemi group; PMID: 34884539) | 2021 |
| FSH on female folliculogenesis | Clinical (FSHR inactivation women) | Complete FSHR inactivation results in complete early blockage of folliculogenesis at primary stage in women; high ovarian reserve persists (follicles fail to be recruited beyond primary stage); confirms FSH is mandatory for human follicular growth beyond primary stage. Challenges the traditional view of gonadotropin-independent early folliculogenesis in humans. | Multiple |
How Does HMG Compare to Other Reproductive Biology Research Compounds?
| Parameter | HMG (YPB.258) | HCG (YPB.256) | Kisspeptin | Triptorelin / GnRH |
|---|---|---|---|---|
| Active Components | FSH activity (FSHR on Sertoli/granulosa cells) + LH activity (LHCGR on Leydig cells); both via Gs/cAMP/PKA | LH activity only (LHCGR on Leydig cells/luteal cells); Gs/cAMP/StAR; no FSH activity | Kiss1R agonist; GnRH pulse generation; no direct gonadal action | GnRH receptor agonist; pituitary LH/FSH release (acute) or suppression (chronic); upstream of HCG and HMG |
| Primary Testicular Target | Sertoli cells (FSH/FSHR) + Leydig cells (LH/LHCGR) | Leydig cells only (LHCGR) | Hypothalamus (GnRH neurons) | Pituitary gonadotrophs (GnRH receptor) |
| Spermatogenesis Role | Both FSH-dependent Sertoli support AND LH-dependent testosterone; the complete spermatogenesis two-signal toolkit in a single compound | LH signal only (Leydig testosterone); requires HMG addition for complete spermatogenesis support in hypogonadotropic models | Upstream activator of the entire gonadal axis | Upstream pituitary stimulation/suppression; indirect gonadal effects |
| Ovarian Role | Folliculogenesis (FSH) + androgen substrate for aromatase (LH); complete ovarian stimulation for ART models | Ovulation trigger (LH mimic); corpus luteum maintenance; progesterone | Reproductive endocrinology; GnRH surge trigger | Ovarian suppression (chronic continuous dosing); desensitization |
| HPG Axis Position | Gonad level (bypasses hypothalamus and pituitary) | Gonad level (bypasses hypothalamus and pituitary) | Hypothalamus level | Pituitary level |
| WADA Status | S2 Prohibited in males (LH component) | S2 Prohibited in males | Not listed | S2 Prohibited (releasing factors) |
| YPB SKU | YPB.258 — see product | YPB.256 — see guide | YPB.276 — see guide | YPB catalog — see guide |
HMG and HCG are the definitive research pair for reproductive endocrinology: HCG provides the LH-only Leydig cell signal (see the HCG Research Guide); HMG adds the FSH-Sertoli cell signal that HCG cannot provide. For upstream HPG axis research, Kisspeptin (see the Kisspeptin Research Guide) activates the GnRH pulse generator — the hypothalamic signal that drives pituitary FSH and LH release — providing the complete HPG axis research toolkit from hypothalamus to gonad.
What Should Researchers Know About HMG Handling?
Glycoprotein Handling
HMG, like HCG, is a glycoprotein preparation. FSH and LH are both heterodimeric glycoproteins sharing the same α-subunit (common to LH, FSH, TSH, and HCG). The critical handling principles: reconstitute gently by directing sterile water or PBS down the vial wall; do not vortex; prepare single-use aliquots to avoid freeze-thaw degradation. For in vitro Sertoli cell research, add HMG to serum-free or low-serum medium; FSH is more stable in culture medium than most synthetic peptides but is still degraded over 24–48 hours by proteases in serum-containing media.
IU Measurement and FSH:LH Ratio
HMG activity is measured in International Units (IU) per vial, with the FSH:LH ratio depending on the specific preparation type. Standard HMG preparations (Pergonal-type): approximately 75 IU FSH + 75 IU LH per vial. Highly purified HMG (hp-hMG; Menopur-type): primarily FSH activity with reduced LH component. For research protocols requiring FSH-specific effects only, hp-hMG or recombinant FSH (if available) provides more selective FSHR stimulation. Research should specify which preparation type was used in protocols, as the FSH:LH ratio affects results.
COA Verification
HMG COA should include: HPLC purity, SDS-PAGE confirmation of FSH and LH subunit bands, bioactivity confirmation (FSH receptor-mediated cAMP or inhibin B induction in Sertoli cell or FSHR-expressing cell assay), IU potency verified against WHO FSH and LH reference preparations, endotoxin (<1 EU/mg), TAMC, and TYMC. Both FSH and LH bioactivity should be confirmed in the COA for standard HMG preparations. All YPB HMG batches include lot-traceable COA documentation through the COA Library.
Key Research Findings
- Two-cell, two-gonadotropin model: LH/HCG → Leydig cells (testosterone); FSH/HMG → Sertoli cells (germ cell support). Both signals independently required for complete spermatogenesis; neither alone is sufficient in hypogonadotropic models.
- FSHR Gs/cAMP/PKA/CREB cascade: Drives Sertoli cell-specific gene program: ABP (intratesticular T concentrator), inhibin B (pituitary feedback/Sertoli function biomarker), GDNF (spermatogonial stem cell maintenance), BTB tight junctions, activin/follistatin (germ cell differentiation). Inhibin B is the primary acute FSHR activation readout in isolated Sertoli cell models.
- FSHRKO mice: severely impaired spermatogenesis despite normal T: FSH/Sertoli signal is independently required even when Leydig testosterone is intact; confirms FSH adds non-testosterone, non-redundant support for germ cell development.
- HCG + HMG spermatogenesis: 70–90% success: Combined protocol is the clinical standard for hypogonadotropic hypogonadism; timing matters (HCG first, then add HMG/FSH after testicular volume/T established).
- FSH mandatory for human folliculogenesis beyond primary stage: FSHR inactivation in women causes complete block at primary follicle stage; challenges gonadotropin-independent early folliculogenesis dogma.
- Highly purified vs. standard HMG: hp-hMG has greater FSHR specificity; standard HMG has ~1:1 FSH:LH; specify preparation type in research protocols; FSH:LH ratio affects results.
- WADA S2 Prohibited in males (LH component): FSH component is not the WADA rationale; the LH activity stimulating testosterone is.
- IU measurement (not mg): Both FSH and LH IU potency should be confirmed in COA; HPLC purity alone is insufficient for glycoprotein mixture bioactivity verification.
Browse the Full Research Catalog
Market Demand and Research Interest
| Demand Indicator | HMG Data Point |
|---|---|
| Clinical context | research-grade compound preparations (Menopur, Repronex, Pergonal) for ovulation induction and ART; cornerstone of hypogonadotropic hypogonadism fertility protocols |
| Unique catalog position | Only FSH+LH dual gonadotropin in YPB catalog; complementary to HCG (LH-only); together they provide the complete two-gonadotropin spermatogenesis toolkit and full ART ovarian stimulation protocol |
| Research communities | Reproductive endocrinology; andrology; ART/IVF research; spermatogenesis biology; Sertoli cell biology; FSHR pharmacology; granulosa cell biology |
| Disease model relevance | Hypogonadotropic hypogonadism; male infertility/azoospermia; female infertility/anovulation; Kallmann syndrome; FSHR mutation biology; spermatogenic failure |
| Paired demand | Nearly every research protocol using HCG for male fertility research also requires FSH/HMG; paired purchase demand is high — researchers who buy HCG for fertility models almost universally need HMG too |
| Keyword difficulty range | Medium (KD 15–25); well-established reproductive endocrinology audience |
How Can Researchers Offer HMG Under Their Own Brand?
Wholesale Pricing & Margin Analysis
| SKU | Compound | Premier ($497/mo) | Core ($297/mo) | Suggested MSRP | Premier Margin |
|---|---|---|---|---|---|
| YPB.258 (RUO) | HMG (Human Menopausal Gonadotropin; FSH + LH) | TBC Premier | TBC Core | TBC | TBC at Premier tier |
Contact the YPB team for confirmed Premier and Core tier pricing. Use the YPB Profit Calculator to model projected revenue. White-label brands offering both HCG (YPB.256) and HMG (YPB.258) create the only white-label catalog providing the complete two-gonadotropin fertility research toolkit: LH-only Leydig cell signal (HCG) + FSH+LH Sertoli/Leydig dual signal (HMG). Paired demand is high: researchers using HCG for hypogonadotropic hypogonadism models almost always need FSH/HMG to complete the spermatogenesis protocol. Download the full catalog for all reproductive endocrinology category pricing.
Methodology & Data Sources
Methodology & Data Sources
Scientific literature: PubMed searched for “human menopausal gonadotropin,” “HMG FSH spermatogenesis,” “FSHR Sertoli cell,” and “FSH folliculogenesis mechanism.” Search conducted through April 2026.
Key sources: Huhtaniemi et al. (2021) Int J Mol Sci (PMID: 34884539; LH/FSH roles review; FSHRKO/LuRKO data; LHβ mutation case); PMC7230878 (FSH/FSHR/cAMP/Sertoli mechanism review); PMC8344352 (FSH/Sertoli cell molecular mechanisms); PMC6302021 (FSH spermatogenesis roles); ScienceDirect HMG overview (HCG+HMG combined protocol data; 70–90% spermatogenesis induction).
Limitations: HMG is a biological mixture (not a single defined molecular entity); FSH:LH ratio and potency vary between preparations and batches; research protocols must specify preparation type. Highly purified hp-hMG and recombinant FSH provide greater receptor selectivity than standard HMG for mechanistic FSH-only research. Research-grade HMG is not equivalent to compound preparations (Menopur, Repronex). This article is for educational purposes only.
References
- Huhtaniemi, I., Alevizaki, M., & Laven, J. (2021). The roles of luteinizing hormone, follicle-stimulating hormone and testosterone in spermatogenesis and folliculogenesis revisited. Int J Mol Sci, 22(23), 12735. PMID: 34884539
- Casas-Gonzalez, P., Scaglia, H. E., Costales-Nieto, C., et al. (2012). Normal reproductive functions in a man with mutant luteinizing hormone. Endocrine. (LHβ mutation maintained spermatogenesis context.)
- FSH action spermatogenesis. (2020). Follicle-stimulating hormone (FSH) action on spermatogenesis: a focus on physiological and therapeutic roles. PMC7230878.
- Bhattacharya, S., et al. (2018). Role of follicle-stimulating hormone in spermatogenesis. Front Endocrinol. PMC6302021. (FSHR pharmacology; FSHRKO data.)
- Sertoli cell molecular mechanisms. PMC8344352. (FSH/FSHR/ABP/inhibin/BTB gene program.)
- ScienceDirect. Human menopausal gonadotropin overview. (HCG + HMG combined protocol; 70–90% spermatogenesis induction; Sertoli cell FSH roles.)
- Dierich, A., Sairam, M. R., Monaco, L., et al. (1998). Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proc Natl Acad Sci USA, 95(23), 13612–13617. (FSHRKO mouse foundational data.)
- Layman, L. C., et al. (1997). Mutations in human gonadotropin-releasing hormone receptor gene cause hypogonadotropic hypogonadism. Nat Genet, 18(1), 14–15. (HPG axis context.)
- European and Israeli Study Group on Highly Purified Menotropin vs. Recombinant FSH. (2002). Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles. Fertil Steril, 78(3), 520–528. (hp-hMG vs. recombinant FSH context.)
Frequently Asked Questions
HMG (human menopausal gonadotropin; hMG; YPB.258) is a urinary-derived glycoprotein preparation containing both FSH activity (binds FSHR on Sertoli cells and granulosa cells; Gs/cAMP/PKA/CREB) and LH activity (binds LHCGR on Leydig cells and luteal cells; Gs/cAMP/StAR). In research models, the FSH component drives Sertoli cell gene programs: ABP (intratesticular testosterone concentrator), inhibin B (pituitary feedback; Sertoli function biomarker), GDNF (spermatogonial stem cell maintenance), BTB tight junction proteins, and activin/follistatin (germ cell differentiation pace). The LH component provides additional Leydig cell testosterone signal (same pathway as HCG but shorter half-life). HMG is used primarily in the combined HCG + HMG protocol for spermatogenesis induction in hypogonadotropic hypogonadism models, where HCG provides Leydig cell testosterone and HMG adds the FSH-dependent Sertoli cell support neither compound provides alone. Published combined protocol: 70–90% sperm induction in hypogonadotropic hypogonadism. WADA S2 Prohibited in males (LH component). Research-grade ≠ Menopur/Pergonal. Research Use Only (RUO). Updated April 2026.
HCG (and endogenous LH) acts exclusively on Leydig cells in the testicular interstitial space via LHCGR, driving testosterone synthesis. HCG has no direct effect on Sertoli cells because Sertoli cells do not express LHCGR; they express FSHR (FSH receptor) instead. Spermatogenesis requires two independently indispensable signals: (1) intratesticular testosterone from Leydig cells (provided by HCG/LH); and (2) FSH-mediated Sertoli cell activation (provided by FSH/HMG). The FSHR/cAMP/PKA/CREB cascade in Sertoli cells drives production of androgen-binding protein (which concentrates testosterone at the germ cell interface), GDNF (which maintains spermatogonial stem cell self-renewal), activin and follistatin (which regulate meiotic pace), and BTB tight junction proteins (which maintain the immunological barrier protecting post-meiotic germ cells). Without these FSH-dependent Sertoli cell outputs, germ cells cannot complete spermatogenesis regardless of testosterone concentration. This is confirmed by FSHRKO (FSH receptor knockout) mice, who retain normal Leydig cell testosterone but show severely impaired spermatogenesis and fertility — because the Sertoli cell signal is absent despite adequate testosterone.
Inhibin B is a dimeric glycoprotein hormone (α/βB heterodimer) produced by Sertoli cells in direct response to FSH stimulation (FSHR/cAMP/PKA activation). It serves two functions: (1) physiologically, it is the primary negative feedback signal from Sertoli cells to the pituitary that suppresses FSH secretion (the FSH-inhibin B feedback loop); and (2) clinically and experimentally, it is the most selective serum (or conditioned medium) biomarker of Sertoli cell function and FSH responsiveness. For FSH/Sertoli cell research with HMG: inhibin B secretion measurable in conditioned medium from primary Sertoli cell cultures at 24–48 hours post-HMG treatment is the most direct confirmation that FSHR activation occurred and Sertoli cell gene programs were induced. Unlike testosterone (which reflects Leydig cell function via LHCGR), inhibin B is exclusively Sertoli-derived and specifically FSH-responsive — it is therefore the ideal endpoint for confirming that the FSH component of HMG (rather than the LH component) produced the observed effect. Clinically, low serum inhibin B in infertile men indicates Sertoli cell dysfunction or depletion; high FSH with low inhibin B is the hormonal signature of primary spermatogenic failure.
Standard HMG (Pergonal-type preparations) is a relatively crude urinary extract containing approximately 75 IU FSH + 75 IU LH per vial (1:1 FSH:LH ratio) with a substantial proportion of the total protein being inactive urinary proteins that are not FSH or LH. These inactive proteins can introduce batch-to-batch variability and may produce nonspecific effects in cell culture models at high concentrations. Highly purified HMG (hp-hMG; Menopur-type) undergoes additional purification steps that dramatically reduce inactive urinary proteins; the resulting preparation has greater FSH receptor specificity but still retains some LH activity. For research purposes: standard HMG is sufficient for combined HCG + HMG spermatogenesis models where both FSH and LH signals are desired; hp-hMG is preferable for mechanistic Sertoli cell research where maximal FSH-receptor selectivity and minimal inactive protein contamination are important. For FSH-only receptor pharmacology research with no LH component, recombinant FSH (if available) provides the highest receptor selectivity. When specifying HMG preparations in published research protocols, distinguishing between standard HMG and hp-hMG is important because the FSH:LH ratio and purity affect reproducibility.
In the ovary, FSHR is expressed on granulosa cells (the somatic cells surrounding the oocyte). FSH binding to granulosa cell FSHR drives Gs/cAMP/PKA/CREB-mediated transcription programs: (1) CYP19A1 (aromatase) upregulation, enabling granulosa cells to convert androstenedione (from theca cells, which express LHCGR for LH/androgen synthesis) to estradiol — the primary source of ovarian estradiol; (2) follicle growth and proliferation of granulosa cells, increasing the follicle’s estrogen production and overall follicular development; (3) antrum formation (fluid-filled cavity development) as follicles transition from preantral to antral stage; (4) LH receptor (LHCGR) expression upregulation on pre-ovulatory granulosa cells, priming them to respond to the HCG trigger for ovulation and luteinization; (5) inhibin A production (ovarian negative FSH feedback during the follicular phase). Loss-of-function FSHR mutations in women cause complete folliculogenesis arrest at the primary follicle stage with primary amenorrhea and infertility, demonstrating that FSH is mandatory for follicular growth beyond the primary stage in humans. For ART research, HMG (FSH+LH activity) is used for controlled ovarian stimulation: FSH drives multi-follicle recruitment and growth; HCG provides the ovulation trigger after FSH-primed follicles express adequate LH receptors.
Yes. YourPeptideBrand.com provides white-label dropship for HMG as YPB.258 (Research Use Only). White-label storefronts include pre-built RUO-compliant product pages with FSHR/cAMP/Sertoli mechanism descriptions, two-cell two-gonadotropin model context, combined HCG + HMG spermatogenesis protocol context, WADA S2 prohibited status clearly noted for males, and COA library links. Contact the YPB team for confirmed Premier and Core pricing, and use the profit calculator to model projected revenue.
Every HMG batch includes a lot-specific COA: HPLC purity, SDS-PAGE confirmation of FSH and LH subunit bands (both α-subunit and respective β-subunits), bioactivity confirmation (FSH receptor-mediated cAMP or inhibin B induction in Sertoli cell or FSHR-expressing cell assay AND LH receptor-mediated cAMP or testosterone induction in Leydig cell or LHCGR-expressing cell assay), IU potency for both FSH and LH components (verified against WHO reference preparations), endotoxin (<1 EU/mg), TAMC, and TYMC. Both FSH and LH bioactivity confirmation is critical for standard HMG — the FSH:LH ratio must be specified to enable appropriate research protocol design. All lots are traceable through the batch-specific COA library.
HCG and HMG are the gonadotropin research pair — complementary, not competing. Position them as “the complete spermatogenesis toolkit”: HCG activates the Leydig cell testosterone pathway (signal 1); HMG activates the Sertoli cell FSH pathway (signal 2). The clinical protocol narrative is compelling: in hypogonadotropic hypogonadism, HCG alone for 3–6 months establishes testicular testosterone and volume; adding HMG initiates spermatogenesis. Neither compound alone achieves what both together do. Nearly every researcher using HCG for male fertility models needs HMG to complete the protocol — paired demand is inherently high. For catalog copy: “HCG + HMG: the two-gonadotropin protocol that induces spermatogenesis in 70–90% of hypogonadotropic models.” Both products also serve female ART research audiences: HMG for controlled ovarian stimulation; HCG for ovulation trigger — again, nearly always used together in IVF protocols. The paired catalog offer directly mirrors real clinical and research workflow.
Key Takeaways
Research Takeaways
- Two-cell, two-gonadotropin model: LH/HCG → Leydig cells (testosterone); FSH/HMG → Sertoli cells (germ cell support). Both independently required; neither alone completes spermatogenesis in hypogonadotropic models.
- FSHR Gs/cAMP/PKA/CREB cascade: Sertoli cell program: ABP (T concentrator), inhibin B (Sertoli function biomarker/pituitary feedback), GDNF (SSC maintenance), BTB junctions, activin/follistatin. Inhibin B is the primary FSHR activation assay readout.
- FSHRKO mice: impaired spermatogenesis despite normal T: FSH signal is independently required even with intact testosterone; confirms non-redundant Sertoli cell FSH function.
- 70–90% spermatogenesis induction (HCG + HMG): Clinical standard for hypogonadotropic hypogonadism; HCG first then add HMG after testosterone/testicular volume established.
- Specify FSH:LH ratio in protocols: Standard HMG ~1:1; hp-hMG >FSH selective; different preparations produce different results. Batch-specific COA FSH:LH potency confirmation required.
- Glycoprotein: gentle reconstitution; no vortex; IU not mg dosing.
Business Takeaways
- Only FSH+LH dual gonadotropin in YPB catalog — adds the FSH/Sertoli signal HCG cannot provide.
- Paired demand with HCG is near-universal — any researcher using HCG for fertility research almost always needs HMG; catalog pair drives both conversions.
- HCG + HMG + Kisspeptin covers the complete HPG axis: gonadal (HCG/HMG), pituitary/hypothalamic (Kisspeptin) from a single reproductive endocrinology buyer audience.
- Contact YPB for confirmed pricing on YPB.258.
Ready to add HMG to your research catalog? Book a consultation with the YPB team.
[ypb_studies peptide=”hmg”]